Biocon vs Wockhardt vs Strides Pharma Science: Which Stock Should You Track

Biocon PE 153.96, mkt cap Rs 64,234 crore. Wockhardt PE 91.44, mkt cap Rs 37,857 crore. Strides Pharma Science PE 17.80, mkt cap Rs 11,294 crore.

Updated: 24 Sept 2026 • 9:57 am

Posted by:

Biocon vs Wockhardt vs Strides Pharma Science: Which Stock Should You Track

Quick Answer

Biocon vs Wockhardt vs Strides Pharma Science is a side-by-side comparison of three companies from the Biotech and Formulations space. On this comparison, Biocon carries a market capitalisation of about Rs 64,234 crore against Rs 37,857 crore for Wockhardt and Rs 11,294 crore for Strides Pharma Science, with return on equity of 1.14%, 5.75% and 17.90% respectively. Each company's numbers are presented here without a declared better pick, since the right stock depends on an investor's own criteria.

Biocon vs Wockhardt vs Strides Pharma Science starts with the core numbers most investors compare within the Biotech and Formulations segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of September 2026 and will shift with daily price moves.

All three names sit in the Biotech and Formulations bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.

Click Here – Get Free Investment Predictions

Table of Contents

Biocon, Wockhardt and Strides Pharma Science: Company Overview

Biocon is a listed Indian company in the Biotech and Formulations space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.

Wockhardt is a listed Indian company in the Biotech and Formulations space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.

Strides Pharma Science is a listed Indian company in the Biotech and Formulations space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.

Biocon vs Wockhardt vs Strides Pharma Science: Valuation and Profitability Snapshot

Metric	Biocon	Wockhardt	Strides Pharma Science
Market Cap (approx.)	Rs 64,234 crore	Rs 37,857 crore	Rs 11,294 crore
PE Ratio (TTM)	153.96	91.44	17.80
PB Ratio	1.86	7.66	3.63
Return on Equity (ROE)	1.14%	5.75%	17.90%
EPS (TTM, Rs)	2.56	25.48	68.83
Dividend Yield	0.13%	0.00%	0.41%
Debt to Equity	0.45	0.45	0.57
Book Value per Share (Rs)	211.51	304.03	337.15

Check the Univest Screener for Live Data

On valuation, Biocon trades at a PE of 153.96 and a PB of 1.86, Wockhardt at a PE of 91.44 and a PB of 7.66, while Strides Pharma Science trades at a PE of 17.80 and a PB of 3.63. On return on equity, the three post 1.14%, 5.75% and 17.90% respectively, and on dividend yield they stand at 0.13%, 0.00% and 0.41%.

Biocon vs Wockhardt vs Strides Pharma Science: Latest Quarterly Results

Company	Latest Quarter Revenue	Latest Quarter Net Profit	YoY Change (Revenue)	QoQ Change (Revenue)
Biocon	Rs 4,390.50 crore	Rs 136.80 crore	+9.2%	-3.9%
Wockhardt	Rs 960.00 crore	Rs 107.00 crore	+26.6%	-5.0%
Strides Pharma Science	Rs 1,270.30 crore	Rs 165.49 crore	+12.6%	-4.6%

Quarterly figures above are the most recent reported quarter for each company (Q1 FY28, quarter ended June 2026), compared with the year-ago and preceding quarter.

Download the Univest iOS App or Univest Android App to track Biocon, Wockhardt and Strides Pharma Science live prices.

What Should Investors Look at Beyond These Numbers?

Beyond the metrics above, investors comparing these three biotech and formulations names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and any sector-specific regulatory developments, since a single-quarter snapshot can shift quickly.

Conclusion

Biocon vs Wockhardt vs Strides Pharma Science highlights how differently three companies in the same biotech and formulations segment can score across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.

Disclaimer: Data and figures in this article are sourced from publicly available information as of September 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on Biocon vs Wockhardt vs Strides Pharma Science

What is the market cap difference between Biocon, Wockhardt and Strides Pharma Science?

Ans. As of September 2026, Biocon has a market cap of approximately Rs 64,234 crore, Wockhardt is at approximately Rs 37,857 crore, and Strides Pharma Science is at approximately Rs 11,294 crore.

Which of the three has the highest PE ratio?

Ans. Among Biocon, Wockhardt and Strides Pharma Science, the PE ratios stand at 153.96, 91.44 and 17.80 respectively as of September 2026.

Which of the three has the highest ROE?

Ans. Biocon, Wockhardt and Strides Pharma Science post ROE of 1.14%, 5.75% and 17.90% respectively as of September 2026.

Which of these three stocks pays the highest dividend yield?

Ans. Biocon, Wockhardt and Strides Pharma Science carry dividend yields of 0.13%, 0.00% and 0.41% respectively.

What is the debt to equity ratio for Biocon, Wockhardt and Strides Pharma Science?

Ans. Biocon carries a debt to equity of 0.45, Wockhardt of 0.45, and Strides Pharma Science of 0.57.

Which of the three trades at the highest price to book value?

Ans. Biocon, Wockhardt and Strides Pharma Science trade at price to book ratios of 1.86, 7.66 and 3.63 respectively.

Is one of Biocon, Wockhardt or Strides Pharma Science better than the others?

Ans. This comparison does not declare one stock better than another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor's own criteria and research.